drugset / Trial / NCT00247481
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.
Timeline
- Start
- 2002-09
- Primary completion
- —
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |